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Edited by Michael R. BubbAbstract Dysfunction of E-cadherins often results in metastasis
of cancerous cells. Here we show that p35, a critical regulator of
cyclin-dependent kinase 5 (CDK5), speciﬁcally depletes the pre-
cursor form of E-cadherin, but not the mature form, by using a
precursor-speciﬁc antibody. Most intriguingly, this downregula-
tion of precursor E-cadherin by p35 is unequivocally independent
of CDK5. Moreover, we found that p35 forms complexes with E-
cadherin proteins. We also found that p35 co-expression can tar-
get E-cadherin to lysosomes and that p35-triggered disappear-
ance of E-cadherin precursor can be blocked speciﬁcally by
lysosomal protease inhibitors, indicating that p35 induces endo-
cytosis and subsequent degradation of precursor E-cadherin.
Structured summary:
MINT-6276674, MINT-6276685:
E-cadherin http://mint.bio.uniroma2.it/mint-curation/search/
interactor.do?interactorAc=MINT-121804 & (uniprotkb:
P09803) physically interacts (MI:0218) with p35 (uniprotkb:
P61809) by coimmunoprecipitation (MI:0019)
MINT-6276701, MINT-6276714:
Cdk5 (uniprotkb:P49615) physically interacts (MI:0218) with
p35 (uniprotkb:P61809) by coimmunoprecipitation (MI:0019)
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cyclin-dependent kinase 5 (CDK5) shares sequence similar-
ity with members of the superfamily of cyclin-dependent ki-
nases [1]. A peculiar feature of CDK5 is that it does not
exert canonical CDK functions that are related to cell cycle; in-
stead, CDK5 seems to play critical roles in neuronal survival
and paradoxically neuronal apoptosis, neuronal migration
and axon guidance, as well as synaptic neurotransmission [2].
Like other cyclin-dependent kinases, CDK5 requires associa-
tion of a regulatory activator, p35 or p39 that shares little se-Abbreviations: CDK5, cyclin-dependent kinase 5; dn, dominant
negative; PCR, polymerase chain reaction
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doi:10.1016/j.febslet.2008.02.053quence identity with cyclins [3–5]. p35 and p39 are targeted to
the cell membrane by virtue of their N-terminal myristoylation
signal [6,7]. They are proteolytically cleaved into p25 and p29,
respectively, by calpain that is activated by elevated intracellu-
lar calcium levels upon stimulation by neurotoxic insults
including ischemic and oxidative damages [7,8]. Whereas p35
is relatively short-lived, p25 has a long life-span and is believed
to cause over-activity of CDK5 in neurons that exhibit patho-
logical conditions. It is important to note that p35 may also act
as an adaptor for various substrates to be phosphorylated by
CDK5. The p35-interacting proteins include b-catenin,
Pctaire1, mSds3 and so on [9–11].
CDK5/p35 plays important roles in the adhesion and migra-
tion of neuronal cells. Many known CDK5 substrates in neu-
rons are cytoskeleton-associated proteins. In particular,
CDK5 has been reported to interact with b-catenin through its
regulatory subunit, p35, and regulates the aﬃnity of b-catenin
for cadherin by altering the phosphorylation levels of b-catenin
in neurons [12,13]. In addition, it has also been shown that
CDK5 plays a role in the regulation of cell adhesion and migra-
tion in lens epithelial cells, corneal epithelial cells and keratino-
cytes [14–16]. Cadherin–catenin complexes play pivotal roles in
cell adhesion [17]. Mature E-cadherin requires correct proteo-
lytic processing, which will remove the N-terminal region from
the precursor of E-cadherin. Similar to mature E-cadherin,
unprocessed E-cadherin can also be plasmamembrane localized
and has features in common with the mature protein, such as
catenin binding and Ca2+-dependent resistance to proteolytic
degradation [18,19]. However, cells expressing the unprocessed
form exhibit no E-cadherin dependent cell aggregation. Proteo-
lytic removal of precursor segment results in the activation of
adhesive properties, demonstrating that the presence of the pre-
cursor segment suppresses the cell adhesion function.
We have been interested in the biological functions and
mechanisms of molecular components in the Wnt pathway.
In an attempt to address how cadherin/b-catenin complex for-
mation might regulate the cellular abundance of b-catenin, we
tested several known or potential related regulators. As a re-
sult, we found that p35 drastically downregulated the precur-
sor form of E-cadherin, and surprisingly that CDK5 kinase
activity was not involved in such an eﬀect. Addition of ammo-
nium chloride or chloroquine but not proteasomal inhibitors
signiﬁcantly attenuated the downregulation, suggesting that
the E-cadherin precursor is downregulated as a result of p35-
enhanced endocytosis and subsequent lysosomal degradation.
Consistently, based on a dextran colocalization experiment,blished by Elsevier B.V. All rights reserved.
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cadherin precursor in lysosomes.Fig. 1. E-cadherin precursor is associated and is downregulated by
p35. (A) The precursor form of E-cadherin is speciﬁcally reduced by
co-expression of p35. HEK 293T cells were transfected with E-
cadherin, GFP, with p35 or p39. After 24 h of transfection, total cell
lysates (TCL) were analyzed by Western blotting using various
antibodies indicated. (B) Time course of the eﬀect of p35 coexpression
on the levels of mature E-cadherin. Cells were transfected with E-
cadherin, and GFP as an internal control. The cells were then
transfected at 12, 18 and 24 h after E-cadherin expression, and were
harvested at 42 h post-transfection of E-cadherin, allowing for p35
expression for 30, 24 and 18 h, as indicated. TCLs were analyzed by
Western blotting using various antibodies indicated. (C) Full length
p35 is required for downregulation of E-cadherin precursor. Cells were
transfected with E-cadherin, full length p35, p10, p25 or GFP as a
control. TCL were analysed by Western blotting using various
antibodies indicated.2. Materials and methods
2.1. Plasmid constructions
Full length cDNA encoding mouse E-cadherin was subcloned into
pCMV5 vector from EST clone. C-terminal HA tagged E-cadherin
was cloned through fusing the EST clone with HA-tag using a polymer-
ase chain reaction (PCR)-based approach. p35, p39, CDK5 and domi-
nant negative (dn)CDK5 (D144N) were as described before [10].
p35dn1 (L151N/L152N), p35dn2 (D288A/L289A) were created using
a site directed mutagenesis approach. C-terminally myc-tagged p35,
HA-CDK5 and HA-dnCDK5 were constructed by PCR strategy.
2.2. Preparation of antibodies
Mouse anti-HA (F-7) and anti-Myc (9E10) were purchased from
Santa Cruz Biotech. Rabbit anti-E-cad was raised against amino acids
752–850 of mouse E-cadherin. Rabbit anti-pre antibody was raised
against the PstI–PvuII fragment (amino acids 31–164) of E-cadherin.
Rabbit anti-p35 were purchased from Sigma, rabbit anti-p39 were as
previously described [10].
2.3. Co-immunoprecipitation and Western blotting
Maintenance of HEK 293T cells, transient transfection using PEI
were as previously described [20]. Transiently transfected HEK 293T
cells in 60 mm dishes were lysed in a lysis buﬀer, sonicated and centri-
fuged at 13,200 rpm for 30 min at 4 C. Proteins were immunoprecipi-
tated from the cell lysate with various antibodies as indicated and
Protein A/G Plus-agarose beads (Santa Cruz). Immunoprecipitates or
TCLs were analyzed by Western blotting as previously described [20].
2.4. Immunoﬂuorescent staining and lysosomal colocalization staining
At 24 h post-transfection, 293T cells were ﬁxed in 4% paraformalde-
hyde for 20 min at room temperature. After washing with PBS, cells
were permeabilized with 0.2% Tween-20 in PBS and blocked in 10%
BSA. Rabbit anti-pre antibody (1:1000) was diluted in block solution.
Rhodamine or FITC conjugated anti-rabbit secondary antibody was
used. To determine if E-cadherin is targeted to lysosomes upon coex-
pression with p35, cells on coverslips were incubated with Texas
Red-labeled dextran (Molecular Probes) (0.1 mg/ml) in serum-free
DMEM with 1 mg/ml of BSA for 10 h before ﬁxation. The ﬁxed cells
were then subjected to immunoﬂuorescence staining with anti-precur-
sor-speciﬁc antibody. The staining patterns were visualized with a con-
focal microscope (Leica).3. Results
3.1. The precursor form of E-cadherin was speciﬁcally
downregulated by p35
E-cadherin was co-transfected with p35 or p39 into 293T
cells. It was detected as double bands with molecular weights
of about 120 and 135 kDa. However, when co-expressed with
p35, the upper band of E-cadherin was speciﬁcally downregu-
lated, with the expression level of the lower one unchanged
(Fig. 1A). Interestingly, p39, another CDK5 activator that
shares 57% identity with p35 in protein sequence, did not exert
any apparent eﬀect on either form of E-cadherin. To investi-
gate whether the p35-induced disappearance of E-cadherin
precursor would ultimately lead to a decrease of the mature
form of E-cadherin, we ﬁrst transfected E-cadherin into 293T
cells, and then p35 after 12, 18 or 24 h of E-cadherin expres-
sion. The levels of mature form of E-cadherin did not show
any detectable decrease during the time course, indicating that
the E-cadherin precursor that can be downregulated by p35
does not undergo the normal E-cadherin proteolytic process-
ing to yield mature E-cadherin (Fig. 1B).It has been known that E-cadherin is ﬁrstly synthesized as a
135 kDa precursor polypeptide, and then processed to a
120 kDa mature polypeptide. To conﬁrm that the upper band
is the precursor form of E-cadherin, we raised a rabbit poly-
clonal antibody against the N-terminal PstI–PvuII fragment
(amino acids 31–164) in the precursor region of E-cadherin.
With this antibody (designated as anti-pre), a single species
corresponding to the upper band was detected and found to
be indeed downregulated by coexpression of p35 (Fig. 1A).
Of note, no band corresponding to the precursor fragment
was detected, further indicating that the disappearance of pre-
cursor was not a result of proteolytic processing. Neither the
p25 fragment of p35, which is more stable than p35 and can
lead to sustained activation of CDK5, nor the complementary
N-terminal p10 fragment had the downregulating eﬀect on the
E-cadherin precursor as full length p35 (Fig. 1C). These results
indicate that full length p35 seemed to be required for the
downregulation of the precursor of E-cadherin.
As precursor and mature E-cadherin are diﬀerentially local-
ized in the cell, we also carried out immunoﬂuorescence study
in 293T cells. E-cadherin and GFP vector (at the ratio of 5:1)
were transfected with control vector or p35 into subconﬂuent
293T cells. Consistent with the results obtained by Western
blotting analysis (Fig. 1A), the signal of the unprocessed poly-
peptide of E-cadherin detected by anti-pre antibody was
greatly reduced when co-expressed with p35, while the number
Fig. 2. Plasma membrane associated E-cadherin precursor is preferentially reduced by p35 co-expression. (A) 293T cells were transfected with
E-cadherin, GFP or p35. At 24 h post-transfection, cells were stained with anti-pre antibody and hoechst33342. Staining patterns were visualized by a
ﬂuorescent microscope (Olympus). (B) Cells were transfected with E-cadherin, or together with p35, followed by immunoﬂuorescent staining with
anti-pre antibody and hoechst as mentioned above.
Fig. 3. Complex formation between p35 and E-cadherin. (A) Both the
precursor and mature forms of E-cadherin are associated with p35.
Cells were transfected with C-terminally HA-tagged E-cadherin and
p35 alone or in combination. E-cadherin-HA and p35 were separately
immunoprecipitated from TCLs using anti-HA or anti-p35 antibody.
(B) The p25 fragment of p35 is suﬃcient to interact with E-cadherin.
Cells were transfected with C-terminally HA-tagged E-cadherin and c-
terminally myc-tagged p35, p10, p25 or p39. E-cadherin was immu-
noprecipitated by anti-HA antibody.
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showing that the reduced signal of the precursor peptide is not
due to a lower transfection eﬃciency (Fig. 2A). When single
cells were examined, the ectopically expressed precursor form
of E-cadherin was mainly localized close to the plasma mem-
brane with relatively weaker signal in the cytosol (Fig. 2B).
The portion of precursor close to the plasma membrane disap-
peared when co-transfected with p35, leaving the cytosolic por-
tion virtually unaﬀected (Fig. 2B).
3.2. Both the precursor and mature form of E-cadherin
associated with p35
We then tested if p35 might exert its downregulation of pre-
cursor E-cadherin by forming a complex with E-cadherin. We
performed reciprocal co-immunoprecipitation assays using
293T cell lysates that contained ectopically expressed untagged
p35 and E-cadherin with antibodies against C-terminal of E-
cadherin and p35, respectively. Considering the precursor form
of E-cadherin can be downregulated by p35, we pretreated
cells with NH4Cl to inhibit its lysosomal degradation. Both
the precursor and mature form of E-cadherin were detected
in the immunoprecipitate of p35, and p35 detected in the E-
cadherin precipitate (Fig. 3A). These results are consistent with
a previous report showing that E-cadherin was detected in the
p35 immunoprecipitates from human keratinocytes [16].
We next tried to determine the region of p35 required for E-
cadherin association. C-terminally myc-tagged p35, its N-ter-
minal p10, and C-terminal p25 fragment, along with p39 as
a control, were separately co-transfected with E-cadherin. It
was found that p25 fragment but not p10 fragment or p39
was detected in the E-cadherin precipitate (Fig. 3B); indicating
that the p25 fragment was required and suﬃcient to form a
complex with E-cadherin.3.3. p35 downregulates E-cadherin precursor independently of
CDK5 kinase activity
Considering the function of p35 is always associated with
CDK5 and CDK5 is quite abundant in 293T cells (data not
shown), we wondered whether the downregulation of the
Fig. 4. CDK5 kinase activity is not required in p35 mediated E-cadherin precursor degradation. (A) Dominant negative mutant CDK5 (HA-
dnCDK5) did not block p35 mediated E-cadherin precursor degradation. Cells were transfected with E-cadherin, GFP, HA-CDK5, HA-dnCDK5 or
p35 in diﬀerent combination indicated. Total cell lysates were analyzed by Western blotting. (B) p35 mutant L151N/L152N (p35dn1) and D288A/
L289A mutant (p35dn2) did not interact with CDK5. Immunoprecipitation was performed using anti-HA antibody. (C) p35dn1 and p35dn2 retain
full ability to downregulate E-cadherin precursor. Cells were transfected with E-cadherin, GFP with or without p35, p35dn1 or p35dn2. Total cell
lysates were analyzed by Western blotting.
1200 S. Lin et al. / FEBS Letters 582 (2008) 1197–1202precursor of E-cadherin by p35 overexpression was a conse-
quence of activation of endogenous CDK5 kinase activity. To
address this point, we included dominant negative CDK5 and
p35 into our study. Transfection of wild-type or dominant neg-
ative CDK5 (D144N) alone did not change E-cadherin protein
level. Transfection of kinase dead form of CDK5 cannot block
or even diminish the downregulation of unprocessed E-cad-
herin by p35 (Fig. 4A). We also created dominant negative
p35 mutants, p35dn1 (altering leucine 151/152 to asparagines,
L151/152N), and p35dn2 for D288A/L289A as previously de-
scribed [21]. Although p35dn1 and p35dn2 failed to interact
with CDK5 (Fig. 4B), they still downregulated the E-cadherin
precursor to a similar extend as wild-type p35 (Fig. 4C). These
data strongly suggested that p35 downregulation of E-cadherin
is not a consequence of CDK5 activation, but through a CDK5
independent mechanism, in accordance with the observation
that p39 or p25 fragment of p35, both of which can activate
CDK5, has no eﬀect on E-cadherin precursor degradation.
3.4. E-cadherin precursor is degraded via a lysosomal pathway
Its reported that mature E-cadherin can undergo proteaso-
mal degradation and is traﬃcked to and from the cell surface
by exocytic and multiple endocytic pathways. To investigate
the possible contribution of these two major degradation path-
ways in the process of downregulation of unprocessed E-cad-
herin by p35, various lysosomal and proteasomal inhibitors
were tested in the precursor degradation assay. We found that
treating cells with lysosomal inhibitors NH4Cl and chloroquine
prevented the disappearance of E-cadherin precursor triggered
by p35. In contrast, proteasomal inhibitors MG132 and ALLN
did not have such an eﬀect (Fig. 5A-left), although they did sta-
bilize Arkadia, a protein known to undergo proteasomal degra-
dation [22] (Fig. 5A-right). Levels of p35 remained unchangedunder treatment of the lysosomal inhibitors, indicating that p35
is not co-endocytosed or degraded with the precursor (Fig. 5A-
right). These results indicate that the downregulation of E-cad-
herin precursor by p35 is through lysosomal pathway but not
proteasomal degradation.
It has previously been reported that dextrans are internalized
in cells and delivered through endosomal compartments to the
lysosomes. HEK 293T cells were treated with Texas Red-la-
beled dextran for 10 h to label the endocytic-lysosomal com-
partments. When cotransfected with p35, the E-cadherin
precursor exhibited partial colocalization with Texas Red-dex-
tran positive vacuoles (yellow), conforming to the notion that
the disappearance of the precursor was mediated by p35
through lysosomal degradation pathway (Fig. 5B).4. Discussion
It is important to note that although p35 is mostly expressed
in the nervous system, it is also detected in systemic cell types
[14–16,23], consistent with a potential role in controlling the
abundance of precursor E-cadherin in non-neuronal cells.
Alternatively, p35 may control cadherin-related cell adhesion
in the nervous system as some studies have demonstrated that
E-cadherin is also locally and transiently expressed in the devel-
oping nervous system, and that anti-E-cadherin antibody af-
fected the overall morphology of developing brains in vitro
[24]. The processing of E-cadherin into mature form takes place
before it reaches the plasma membrane [19]. The ﬁnding that
p35 did not aﬀect the levels of mature form of E-cadherin, even
after their prolonged coexpression as assessed by expression
time course, indicates that the degraded portion of E-cadherin
precursor would not be later processed into mature E-cadherin.
Fig. 5. E-cadherin precursor degradation mediated by p35 is through a lysosomal pathway. (A) Left, p35 mediated E-cadherin degradation was
blocked by lysosomal inhibitors but not proteasomal inhibitors. About 40 mM NH4Cl, 200 lM chloroquine, 10 lM MG132 or 40 lM ALLN was
added into growth medium 12 h post-transfection and cells were harvested at 24 h post-transfection. Right, proteasomal inhibitors can stabilize
Arkadia, which serves as a positive control for the eﬃcacy of the inhibitors. (B) Colocalization of E-cadherin precursor with TR-dextran in 293T
cells. 293T cells were transfected with E-cadherin alone or with p35. At 18 h post-transfection, cells were incubated with Texas Red-labeled dextran
(0.1 mg/ml) diluted in serum free DMEM with BSA (1 mg/ml). Approximately 10 h after incubation, cells were ﬁxed and stained using anti-
precursor-speciﬁc (anti-pre) antibody and FITC conjugated secondary antibody. Staining patterns were visualized by a confocal microscope (Leica).
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regulator. However, Cyclin D1 has been shown to activate
estrogen receptor independently of CDK, suggesting that the
cyclins may carry out functions independently of their cognate
CDKs [25]. Here, we have unequivocally demonstrated that
p35 can regulate the abundance of E-cadherin precursor with
the involvement of CDK5. First of all, we showed that the ki-
nase-dead form of CDK5 did not attenuate the downregulat-
ing eﬀect of p35 on E-cadherin. Second, the p35 mutants
that cannot interact with and are unable to activate CDK5
can eﬀectively reduce the abundance of E-cadherin precursor.
Moreover, p25, the activating form of p35 for CDK5, on the
contrary fails to exert the same eﬀect as p35. This brings to
another ﬁnding of our current study that an intact p35, but
not p10 or p25, is required for degradation of E-cadherin.
Consistently, tagging of p35, N-terminally or C-terminally
abolished its function, although it did not aﬀect its interaction
with E-cadherin (data not shown). How exactly p35 speciﬁ-
cally regulates the precursor of E-cadherin remains unclear.
It is feasible that p35 may target E-cadherin to degradation
by cooperating with some unknown factors that can discrimi-
nate the precursor form from the mature form. It is thereforeof great interest to test what signals may upregulate p35 levels
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